Rivaroxaban Reduces Heart Attack, Stroke and Death in Patients With ACS
Posted Nov 14 2011 5:27pm
Rivaroxaban (Xarelto) is an anti-blood clotting medicine currently approved to reduce the risk of stroke and blood clots in patients with atrial fibrillation (abnormal heart rhythm) not caused by a heart valve problem. Now researchers at Brigham and Women’s Hospital (BWH), Beth Israel Deaconess Medical Center (BIDMC), and Harvard Medical School have investigated whether rivaroxaban can also help patients with an acute coronary syndrome (ACS). ACS is a collection of signs and symptoms (e.g., chest pain) caused by reduced blood flow to the heart.
The study will be electronically published in The New England Journal of Medicine on November 13. It will also be presented at this year’s American Heart Association’s Scientific Sessions in Orlando, Florida occurring Nov. 12-16.
The ATLAS ACS 2-TIMI 51 (Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome) study found that, when added to standard medical treatment, rivaroxaban reduced the risk of heart attack, stroke or cardiovascular death in patients recently diagnosed with ACS.
Rivaroxaban (Xarelto) is an anti-blood clotting medicine currently approved to reduce the risk of stroke and blood clots in patients with atrial fibrillation (abnormal heart rhythm) not caused by a heart valve problem. Now researchers at Brigham and Women’s Hospital (BWH), Beth Israel Deaconess Medical Center (BIDMC), and Harvard Medical School have investigated whether rivaroxaban can also help patients with an acute coronary syndrome (ACS). ACS is a collection of signs and symptoms (e.g., chest pain) caused by reduced blood flow to the heart.
The study will be electronically published in The New England Journal of Medicine on November 13. It will also be presented at this year’s American Heart Association’s Scientific Sessions in Orlando, Florida occurring Nov. 12-16.
The ATLAS ACS 2-TIMI 51 (Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome) study found that, when added to standard medical treatment, rivaroxaban reduced the risk of heart attack, stroke or cardiovascular death in patients recently diagnosed with ACS.